Abstract
Most lymphoma types are fluorodeoxyglucose positron emission tomography (FDG-PET) positive, and FDG-PET/computed tomography (CT) is used routinely in staging and treatment evaluation of lymphomas. PET/CT imaging is important for contouring of the target for radiotherapy and changes the radiation volumes significantly compared with radiotherapy planning based on CT alone. Modern advanced imaging techniques with image fusion and inspiration breath hold have enabled further refinements of radiotherapy for lymphoma, reducing the risks of long-term side effects while maintaining the high cure rate for these diseases.
Similar content being viewed by others
References
Illidge T, Specht L, Yahalom J, Aleman B, Berthelsen AK, Constine L, Dabaja B, Dharmarajan K, Ng A, Ricardi U, Wirth A (2014) Modern radiation therapy for nodal non Hodgkin lymphoma—target definition and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG). Int J Radiat Oncol Biol Phys 89:49–58
Specht L, Yahalom J, Illidge T, Berthelsen AK, Constine LS, Eich HT, Girinsky T, Hoppe RT, Mauch P, Mikhaeel NG, Ng A (2014) Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). Int J Radiat Oncol Biol Phys 89:854–862
Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R, Wirth A (2015) Modern radiation therapy for extranodal lymphomas: field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys 92:11–31
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3068
Barrington SF, Mikhaeel NG (2014) When should FDG-PET be used in the modern management of lymphoma? Br J Haematol 164(3):315–328
Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di RF, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-d-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752
Haioun C, Itti E, Rahmouni A, Brice P, Rain JD, Belhadj K, Gaulard P, Garderet L, Lepage E, Reyes F, Meignan M (2005) [18F]fluoro-2-deoxy-d-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood 106:1376–1381
Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59
Jerusalem G, Beguin Y, Fassotte MF, Najjar F, Paulus P, Rigo P, Fillet G (2000) Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin’s lymphoma. Haematologica 85:613–618
Kostakoglu L, Coleman M, Leonard JP, Kuji I, Zoe H, Goldsmith SJ (2002) PET predicts prognosis after 1 cycle of chemotherapy in aggressive lymphoma and Hodgkin’s disease. J Nucl Med 43:1018–1027
Mikhaeel NG, Hutchings M, Fields PA, O’Doherty MJ, Timothy AR (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Ann Oncol 16:1514–1523
Mylam KJ, Kostakoglu L, Hutchings M, Coleman M, Lamonica D, Czuczman MS, Diehl LF, Nielsen AL, Jensen P, Loft A, Hendel HW, Iyer V, Leppa S, Jyrkkio S, Holte H, Eriksson M, Gillstrom D, Hansen PB, Seppanen M, Hjorthaug K, Brown PD, Pedersen LM (2014) F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma 20:1–8
Rigacci L, Puccini B, Zinzani PL, Biggi A, Castagnoli A, Merli F, Balzarotti M, Stelitano C, Spina M, Vitolo U, Stefoni V, Levis A, Gotti M, Rosaria S, Maria SP, Bosi A, Gallamini A (2015) The prognostic value of positron emission tomography performed after two courses (INTERIM-PET) of standard therapy on treatment outcome in early stage Hodgkin lymphoma: a multicentric study by the fondazione italiana linfomi (FIL). Am J Hematol 90(6):499–503
Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, Balzarini J, De Wolf-Peeters C, Mortelmans L, Verhoef G (2002) Early restaging positron emission tomography with (18)F-fluorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin’s lymphoma. Ann Oncol 13:1356–1363
Zinzani PL, Quaglino P, Pimpinelli N, Berti E, Baliva G, Rupoli S, Martelli M, Alaibac M, Borroni G, Chimenti S, Alterini R, Alinari L, Fierro MT, Cappello N, Pileri A, Soligo D, Paulli M, Pileri S, Santucci M, Bernengo MG (2006) Prognostic factors in primary cutaneous B-cell lymphoma: the Italian Study Group for Cutaneous Lymphomas. J Clin Oncol 24:1376–1382
Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johnson P, Wimperis J, Culligan D, Popova B, Smith P, McMillan A, Brownell A, Kruger A, Lister A, Hoskin P, O’Doherty M, Barrington S (2015) Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med 372:1598–1607
Raemaekers JM, Andre MP, Federico M, Girinsky T, Oumedaly R, Brusamolino E, Brice P, Ferme C, van der Maazen R, Gotti M, Bouabdallah R, Sebban CJ, Lievens Y, Re A, Stamatoullas A, Morschhauser F, Lugtenburg PJ, Abruzzese E, Olivier P, Casasnovas RO, van IG, Raveloarivahy T, Bellei M, van der Borght T, Bardet S, Versari A, Hutchings M, Meignan M, Fortpied C (2014) Omitting radiotherapy in early positron emission tomography-negative stage i/ii hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194
Savage KJ, Connors JM, Klasa RJ, Hoskins P, Shenkier TN, Gascoyne RD, Bhimji S, Pickles T, Benard F, Wilson D, Sehn LH (2011) The use of FDG-PET to guide consolidative radiotherapy in patients with advanced-stage Hodgkin lymphoma with residual abnormalities on CT scan following ABVD chemotherapy. J Clin Oncol 29(Suppl) (abstr 8034)
Engert A, Haverkamp H, Kobe C, Markova J, Renner C, Ho A, Zijlstra J, Král Z, Fuchs M, Hallek M, Kanz L, Döhner H, Dörken B, Engel N, Topp M, Klutmann S, Amthauer H, Bockisch A, Kluge R, Kratochwil C, Schober O, Greil R, Andreesen R, Kneba M, Pfreundschuh M, Stein H, Eich HT, Müller RP, Dietlein M, Borchmann P, Diehl V (2012) Reduced intensity of chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin lymphoma: an open-label, randomised phase 3 trial. Lancet 379:1791–1799
Kobe C, Kuhnert G, Kahraman D, Haverkamp H, Eich HT, Franke M, Persigehl T, Klutmann S, Amthauer H, Bockisch A, Kluge R, Wolf HH, Maintz D, Fuchs M, Borchmann P, Diehl V, Drzezga A, Engert A, Dietlein M (2014) Assessment of tumor size reduction improves outcome prediction of positron emission tomography/computed tomography after chemotherapy in advanced-stage hodgkin lymphoma. J Clin Oncol 32:1776–1781
Kriz J, Reinartz G, Dietlein M, Kobe C, Kuhnert G, Haverkamp H, Haverkamp U, Engenhart-Cabillic R, Herfarth K, Lukas P, Schmidberger H, Staar S, Hegerfeld K, Baues C, Engert A, Eich HT (2015) Relapse analysis of irradiated patients within the hd15 trial of the german hodgkin study group. Int J Radiat Oncol Biol Phys 92(1):46–53
Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD, Benard F, Wilson D, Morris J, Parsons C, Pickles T, Connors JM, Savage KG (2013) Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large b cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 31(S1):137 (abstract 123)
Girinsky T, Ghalibafian M, Bonniaud G, Bayla A, Magne N, Ferreira I, Lumbroso J (2007) Is FDG-PET scan in patients with early stage Hodgkin lymphoma of any value in the implementation of the involved-node radiotherapy concept and dose painting? Radiother Oncol 85:178–186
Girinsky T, Specht L, Ghalibafian M, Edeline V, Bonniaud G, Van Der MR, Aleman B, Paumier A, Meijnders P, Lievens Y, Noordijk E, Poortmans P (2008) The conundrum of Hodgkin lymphoma nodes: to be or not to be included in the involved node radiation fields. The EORTC-GELA lymphoma group guidelines. Radiother Oncol 88:202–210
Bonadonna G, Bonfante V, Viviani S, Di Russo A, Villani F, Valagussa P (2004) ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin’s disease: long-term results. J Clin Oncol 22(14):2835–2841
Engert A, Schiller P, Josting A, Herrmann R, Koch P, Sieber M, Boissevain F, de Wit M, Mezger J, Duhmke E, Willich N, Muller RP, Schmidt BF, Renner H, Muller-Hermelink HK, Pfistner B, Wolf J, Hasenclever D, Loffler M, Diehl V (2003) Involved-Field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable hodgkin’s lymphoma: results of the HD8 trial of the german hodgkin’s lymphoma study group. J Clin Oncol 21(19):3601–3608
Ferme C, Eghbali H, Meerwaldt JH, Rieux C, Bosq J, Berger F, Girinsky T, Brice P, van’t Veer MB, Walewski JA, Lederlin P, Tirelli U, Carde P, Van Den Neste E, Gyan E, Monconduit M, Divine M, Raemaekers JMM, Salles G, Noordijk EM, Creemers GJ, Gabarre J, Hagenbeek A, Reman O, Blanc M, Thomas J, Vie B, Kluin-Nelemans JC, Viseu F, Baars JV, Poortmans P, Lugtenburg PJ, Carrie C, Jaubert J, Henry-Amar M, The EORTC-GELA H8 Trial (2007) Chemotherapy plus involved-field radiation in early-stage hodgkin’s disease. N Engl J Med 357(19):1916–1927
Girinsky T, Van Der MR, Specht L, Aleman B, Poortmans P, Lievens Y, Meijnders P, Ghalibafian M, Meerwaldt J, Noordijk E (2006) Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. Radiother Oncol 79:270–277
de Bruin ML, Sparidans J, van’t Veer MB, Noordijk EM, Louwman MW, Zijlstra JM, van den Berg H, Russell NS, Broeks A, Baaijens MH, Aleman BM, van Leeuwen FE (2009) Breast cancer risk in female survivors of Hodgkin’s lymphoma: lower risk after smaller radiation volumes. J Clin Oncol 27:4239–4246
Maraldo MV, Brodin NP, Vogelius IR, Aznar MC, Munck Af RP, Petersen PM, Specht L (2012) Risk of developing cardiovascular disease after involved node radiotherapy versus mantle field for Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 83:1232–1237
Maraldo MV, Brodin P, Aznar MC, Vogelius IR, Munck Af RP, Petersen PM, Specht L (2013) Doses to carotid arteries after modern radiation therapy for Hodgkin lymphoma: is stroke still a late effect of treatment? Int J Radiat Oncol Biol Phys 87:297–303
Maraldo MV, Brodin NP, Aznar MC, Vogelius IR, Munck Af RP, Petersen PM, Specht L (2013) Estimated risk of cardiovascular disease and secondary cancers with modern highly conformal radiotherapy for early-stage mediastinal Hodgkin lymphoma. Ann Oncol 24:2113–2118
Berthelsen AK, Dobbs J, Kjellen E, Landberg T, Moller TR, Nilsson P, Specht L, Wambersie A (2007) What’s new in target volume definition for radiologists in ICRU Report 71? How can the ICRU volume definitions be integrated in clinical practice? Cancer Imaging 7:104–116
Filippi AR, Ciammella P, Piva C et al (2014) Involved-site image-guided intensity modulated versus 3D conformal radiation therapy in early stage supradiaphragmatic Hodgkin lymphoma. Int J Radiation Oncol Biol Phys 89(2):370–375
Brianzoni E, Rossi G, Ancidei S, Berbellini A, Capoccetti F, Cidda C, D’Avenia P, Fattori S, Montini GC, Valentini G, Proietti A, Algranati C (2005) Radiotherapy planning: pET/CT scanner performances in the definition of gross tumour volume and clinical target volume. Eur J Nucl Med Mol Imaging 32:1392–1399
Dizendorf EV, Baumert BG, von Schulthess GK, Lutolf UM, Steinert HC (2003) Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 44:24–29
Hutchings M, Loft A, Hansen M, Berthelsen AK, Specht L (2007) Clinical impact of FDG-PET/CT in the planning of radiotherapy for early-stage Hodgkin lymphoma. Eur J Haematol 78:206–212
Lee YK, Cook G, Flower MA, Rowbottom C, Shahidi M, Sharma B, Webb S (2004) Addition of 18F-FDG-PET scans to radiotherapy planning of thoracic lymphoma. Radiother Oncol 73:277–283
Terezakis SA, Hunt MA, Kowalski A, McCann P, Schmidtlein CR, Reiner A, Gonen M, Kirov AS, Gonzales AM, Schoder H, Yahalom J (2011) [(1)(8)F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. Int J Radiat Oncol Biol Phys 81:615–622
Girinsky T, Auperin A, Ribrag V, Elleuch M, Ferme C, Bonniaud G, Ruelle C, Alberini JL, Celebic A, Edeline V (2014) Role of FDG-PET in the implementation of involved-node radiation therapy for Hodgkin lymphoma patients. Int J Radiat Oncol Biol Phys 89:1047–1052
Metwally H, Courbon F, David I, Filleron T, Blouet A, Rives M, Izar F, Zerdoud S, Plat G, Vial J, Robert A, Laprie A (2011) Coregistration of prechemotherapy PET-CT for planning pediatric Hodgkin’s disease radiotherapy significantly diminishes interobserver variability of clinical target volume definition. Int J Radiat Oncol Biol Phys 80:793–799
Robertson VL, Anderson CS, Keller FG, Halkar R, Goodman M, Marcus RB, Esiashvili N (2011) Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 80:324–332
Terezakis SA, Schoder H, Kowalski A, McCann P, Lim R, Turlakov A, Gonen M, Barker C, Goenka A, Lovie S, Yahalom J (2014) A prospective study of (1)(8)FDG-PET with CT coregistration for radiation treatment planning of lymphomas and other hematologic malignancies. Int J Radiat Oncol Biol Phys 89:376–383
Gregoire V (2004) Is there any future in radiotherapy planning without the use of PET: unraveling the myth. Radiother Oncol 73:261–263
Jarritt PH, Carson KJ, Hounsell AR, Visvikis D (2006) The role of PET/CT scanning in radiotherapy planning. Br J Radiol 79(1):S27–S35
Berthelsen AK, Holm S, Loft A, Klausen TL, Andersen F, Hojgaard L (2005) PET/CT with intravenous contrast can be used for PET attenuation correction in cancer patients. Eur J Nucl Med Mol Imaging 32:1167–1175
Aznar MC, Maraldo MV, Schut DA, Lundemann M, Brodin NP, Vogelius IR, Berthelsen AK, Specht L, Petersen PM (2015) Minimizing late effects for patients with mediastinal hodgkin lymphoma: deep Inspiration Breath-Hold, IMRT, or Both? Int J Radiat Oncol Biol Phys 92:169–174
Paumier A, Ghalibafian M, Beaudre A, Ferreira I, Pichenot C, Messai T, Lessard NA, Lefkopoulos D, Girinsky T (2011) Involved-node radiotherapy and modern radiation treatment techniques in patients with Hodgkin lymphoma. Int J Radiat Oncol Biol Phys 80:199–205
Paumier A, Ghalibafian M, Gilmore J, Beaudre A, Blanchard P, el Nemr M, Azoury F, al Hamokles H, Lefkopoulos D, Girinsky T (2012) Dosimetric benefits of intensity-modulated radiotherapy combined with the deep-inspiration breath-hold technique in patients with mediastinal Hodgkin’s lymphoma. Int J Radiat Oncol Biol Phys 82:1522–1527
Petersen PM, Aznar MC, Berthelsen AK, Loft A, Schut DA, Maraldo M, Josipovic M, Klausen TL, Andersen FL, Specht L (2015) Prospective phase II trial of image-guided radiotherapy in Hodgkin lymphoma: benefit of deep inspiration breath-hold. Acta Oncol 54:60–66
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors of this review article (Umberto Ricardi, Lena Specht, Annibale Versari, Anne Kiil Berthelsen) declare that they have no conflict of interest.
Human and animal studies
This article does not contain any studies with human or animal subjects performed by any of the authors.
Rights and permissions
About this article
Cite this article
Ricardi, U., Specht, L., Versari, A. et al. FDG-PET and radiotherapy in lymphoma. Clin Transl Imaging 3, 321–330 (2015). https://doi.org/10.1007/s40336-015-0129-8
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-015-0129-8